#1 Clinical Trials Search in Europe

Beclometasone Dipropionate Anhydrous

This article discusses clinical trials investigating the use of Beclometasone Dipropionate Anhydrous, a corticosteroid medication, in combination with other drugs for treating respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD). The trials aim to evaluate the efficacy, safety, and tolerability of different inhaler formulations containing this drug compared to existing treatments.

Table of Contents

What is Beclometasone Dipropionate Anhydrous?

Beclometasone Dipropionate Anhydrous is a potent corticosteroid medication used in the treatment of respiratory conditions. It is an anti-inflammatory drug that helps reduce swelling and irritation in the airways[1]. This medication is commonly used in inhalers and is part of a class of drugs known as inhaled corticosteroids (ICS).

Medical Conditions Treated

Beclometasone Dipropionate Anhydrous is primarily used to treat:

  • Asthma: It is used for the long-term management of asthma, particularly in patients with moderate to severe asthma[1].
  • Chronic Obstructive Pulmonary Disease (COPD): It is also used in the treatment of COPD, a group of lung diseases that includes chronic bronchitis and emphysema[3].

How It Works

Beclometasone Dipropionate Anhydrous works by reducing inflammation in the airways. When inhaled, it:

  • Decreases the production of inflammatory substances in the lungs
  • Reduces swelling and irritation in the bronchial tubes
  • Helps to prevent asthma attacks and COPD exacerbations
This action helps to improve breathing and reduce symptoms such as wheezing, coughing, and shortness of breath[1].

Administration and Dosage

Beclometasone Dipropionate Anhydrous is typically administered via inhalation. It is available in various forms, including:

  • Pressurized Metered Dose Inhaler (pMDI): A device that delivers a specific amount of medication in a fine mist form[1].
  • Dry Powder Inhaler: A device that delivers the medication in a dry powder form[1].
The dosage varies depending on the severity of the condition and the specific product being used. It’s crucial to follow your healthcare provider’s instructions carefully.

Combination Therapies

Beclometasone Dipropionate Anhydrous is often used in combination with other medications to provide more comprehensive treatment for respiratory conditions. Common combinations include:

  • Beclometasone + Formoterol: This combination includes a long-acting beta-agonist (LABA) to provide both anti-inflammatory and bronchodilating effects[1].
  • Beclometasone + Formoterol + Glycopyrronium: This triple combination therapy includes a long-acting muscarinic antagonist (LAMA) in addition to the ICS and LABA, providing enhanced bronchodilation for COPD patients[3].
These combination therapies can provide more effective symptom control for some patients.

Clinical Studies and Efficacy

Several clinical studies have been conducted to evaluate the efficacy of Beclometasone Dipropionate Anhydrous and its combinations:

  • A study comparing a triple combination of Beclometasone, Formoterol, and Glycopyrronium to a dual combination of Beclometasone and Formoterol in COPD patients showed improved lung function and reduced exacerbation rates with the triple therapy[3].
  • Another study in asthma patients demonstrated that a combination of Beclometasone and Mepolizumab (an anti-IL-5 treatment) improved asthma control and reduced exacerbations[1].
These studies highlight the effectiveness of Beclometasone Dipropionate Anhydrous in managing respiratory conditions, particularly when used in combination with other medications.

Potential Side Effects

While Beclometasone Dipropionate Anhydrous is generally well-tolerated, it may cause some side effects. Common side effects include:

  • Throat irritation
  • Hoarseness
  • Oral thrush (fungal infection in the mouth)
  • Cough
Less common but more serious side effects may include:
  • Increased risk of pneumonia (particularly in COPD patients)
  • Adrenal suppression (with long-term use of high doses)
  • Decreased bone density (with long-term use)
It’s important to discuss any side effects with your healthcare provider[3].

Precautions and Contraindications

Certain precautions should be taken when using Beclometasone Dipropionate Anhydrous:

  • Inform your doctor if you have any fungal, bacterial, or viral infections before starting treatment.
  • If you’re pregnant or breastfeeding, discuss the risks and benefits with your healthcare provider.
  • Long-term use should be monitored by a healthcare professional to minimize potential systemic effects.
  • This medication is not suitable for treating acute asthma attacks or COPD exacerbations – a fast-acting “rescue” inhaler should be used for these situations.
Always follow your doctor’s instructions and do not adjust your dosage without consulting your healthcare provider[3].

Trial Aspect Details
Conditions Studied Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Main Medications Beclometasone Dipropionate Anhydrous, Formoterol Fumarate Dihydrate, Glycopyrronium Bromide
Administration Method Pressurized Metered-Dose Inhalers (pMDI), Dry Powder Inhalers
Primary Objectives Evaluate efficacy, safety, and tolerability of drug combinations
Key Endpoints Lung function improvement (FEV1), reduction in exacerbations, quality of life measures
Study Designs Randomized, double-blind, parallel-group, active-controlled
Trial Durations Up to 52 weeks with follow-up periods
Patient Populations Adults with moderate to severe asthma or COPD

FAQ

  • What conditions are being studied in these clinical trials? The clinical trials are studying asthma and chronic obstructive pulmonary disease (COPD).
  • What is the main drug being investigated? The main drug being investigated is Beclometasone Dipropionate Anhydrous, often in combination with other medications like formoterol fumarate and glycopyrronium bromide.
  • How is the medication administered in these trials? The medication is administered through inhalers, specifically pressurized metered-dose inhalers (pMDI) or dry powder inhalers.
  • What are the main goals of these clinical trials? The main goals are to evaluate the efficacy, safety, and tolerability of the drug combinations, as well as to assess improvements in lung function, reduction in exacerbations, and quality of life for patients.
  • How long do these clinical trials typically last? The duration of the trials varies, but they can last up to 52 weeks, with some including follow-up periods.

Ongoing Clinical Trials on Beclometasone Dipropionate Anhydrous

  • Comparison of CHF5993 (glycopyrronium bromide, formoterol fumarate dihydrate, and beclometasone dipropionate) and a drug combination for patients with mild to moderate asthma

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Germany Hungary Latvia Poland +2

  • Asthma in adults: beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide compared with beclometasone dipropionate and formoterol fumarate dihydrate

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Bulgaria France Germany Italy Poland Romania +2

  • Study comparing CHF 5993 (beclometasone/formoterol/glycopyrronium) to fluticasone/salmeterol inhalation in adolescents with uncontrolled asthma on medium-dose inhaled therapy

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Spain

  • A study testing dust mite allergy extracts from Dermatophagoides pteronyssinus and Dermatophagoides farinae for patients with allergic rhinoconjunctivitis with or without controlled asthma

    Not yet recruiting

    3 1 1
    Investigated drugs:
    Spain

  • Study on the Effectiveness and Safety of CHF 5993 Compared to CHF 1535 for Patients with Chronic Obstructive Pulmonary Disease (COPD)

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Hungary Poland Romania

  • Study on the Safety of CHF5993 Inhaler with HFA-152a vs. HFA-134a in Patients with Moderate to Severe Asthma

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Germany Greece Hungary Italy +5

  • Study on Asthma Control and Adherence with Mepolizumab in Pre-filled Devices for Patients with Asthma

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Beclometasone Dipropionate Anhydrous: A corticosteroid medication used to treat asthma and other respiratory conditions by reducing inflammation in the airways.
  • Formoterol Fumarate Dihydrate: A long-acting beta-2 agonist (LABA) that helps to relax and open the airways in the lungs, making breathing easier.
  • Glycopyrronium Bromide: An anticholinergic medication that helps to widen airways and decrease mucus production in the lungs.
  • Pressurized Metered-Dose Inhaler (pMDI): A device that delivers a specific amount of medication to the lungs in the form of a short burst of aerosolized medicine that is inhaled through the mouth.
  • Chronic Obstructive Pulmonary Disease (COPD): A group of lung diseases, including chronic bronchitis and emphysema, that cause airflow blockage and breathing-related problems.
  • Exacerbation: A worsening of symptoms or an acute episode in chronic diseases like asthma or COPD.
  • Forced Expiratory Volume in 1 second (FEV1): The amount of air a person can forcefully exhale in one second, used to measure lung function.
  • St. George's Respiratory Questionnaire (SGRQ): A standardized questionnaire used to measure health-related quality of life in patients with respiratory diseases.
  • Bronchodilator: A substance that dilates the bronchi and bronchioles, decreasing resistance in the respiratory airway and increasing airflow to the lungs.
  • Inhaled Corticosteroid (ICS): A type of corticosteroid medication that is inhaled directly into the lungs to reduce inflammation and prevent asthma symptoms.

References

  1. http://clinicaltrials.eu/trial/study-on-asthma-control-and-adherence-with-mepolizumab-in-pre-filled-devices-for-patients-with-asthma/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-of-chf5993-inhaler-with-hfa-152a-vs-hfa-134a-in-patients-with-moderate-to-severe-asthma/
  3. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-chf-5993-compared-to-chf-1535-for-patients-with-chronic-obstructive-pulmonary-disease-copd/